Literature DB >> 16249516

Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation.

Jonathan E Sears1, George Hoppe.   

Abstract

PURPOSE: To identify the molecular mechanism of steroid-induced downregulation of vascular endothelial growth factor (VEGF) synthesis in Müller cells.
METHODS: Confluent cultures of human Müller cells (MIO-M1) were treated with 100 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both. VEGF secretion was measured with respect to time by ELISA. VEGF mRNA quantity and stability were analyzed by reverse transcriptase-polymerase chain reaction. The activity of hypoxia-inducible factor (HIF)-1 was measured by the relative binding of HIF-1 protein to the hypoxia response element (HRE), by gel shift and ELISA. The HIF-1alpha protein level was determined with Western blot.
RESULTS: TA decreased VEGF secretion by at least 50% in the presence of continuous cobalt stimulus. VEGF mRNA decreased 50- to 100-fold 6 hours after treatment with TA and cobalt compared with cobalt alone. VEGF mRNA stability was decreased in cobalt-stimulated, TA-treated cells compared with cobalt alone in cells synchronized by exposure to actinomycin D. HIF-1alpha protein level was sustained for the entire 24-hour treatment period and partitioned into nuclear, not cytosolic, fractions. HIF-1 activity was decreased by 20% to 30% in the presence of TA and cobalt compared with cobalt alone.
CONCLUSIONS: TA may decrease VEGF synthesis by nongenomic destabilization of VEGF mRNA in cobalt-stimulated Müller cells. There was little effect on the total HIF-1alpha protein level, HIF-1 partitioning, and HIF-1 activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249516     DOI: 10.1167/iovs.05-0565

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.

Authors:  M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

2.  Vitreous inflammatory factors in macular edema with central retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Seiyo Harino; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

3.  Involvement of A(1) adenosine receptors in osmotic volume regulation of retinal glial cells in mice.

Authors:  Antje Wurm; Stephan Lipp; Thomas Pannicke; Regina Linnertz; Katrin Färber; Peter Wiedemann; Andreas Reichenbach; Andreas Bringmann
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

Review 4.  Corticosteroid use for diabetic macular edema: old fad or new trend?

Authors:  Michael W Stewart
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 5.  Diabetic macular edema: New promising therapies.

Authors:  Hanan N Al Shamsi; Jluwi S Masaud; Nicola G Ghazi
Journal:  World J Diabetes       Date:  2013-12-15

Review 6.  Müller cells as players in retinal degeneration and edema.

Authors:  Andreas Reichenbach; Antje Wurm; Thomas Pannicke; Ianors Iandiev; Peter Wiedemann; Andreas Bringmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-01-12       Impact factor: 3.535

7.  Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema.

Authors:  Hatem M Marey; Amin F Ellakwa
Journal:  Clin Ophthalmol       Date:  2011-07-22

8.  Efficacy of intravitreal triamcinolone acetonide for eyes with postvitrectomy diabetic vitreous hemorrhage.

Authors:  Sun Young Lee; Hee Gyung Lee; Hye-won Chung; Young Hee Yoon; June-Gone Kim
Journal:  Korean J Ophthalmol       Date:  2007-12

9.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

10.  Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon's Capsule Triamcinolone Acetonide Injection.

Authors:  Toshiyuki Oshitari; Yuta Kitamura; Sakiko Nonomura; Miyuki Arai; Yoko Takatsuna; Eiju Sato; Takayuki Baba; Shuichi Yamamoto
Journal:  J Ophthalmol       Date:  2015-09-20       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.